UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING

Core Points - OSE Immunotherapeutics has requested an extension for the Combined General Meeting scheduled for June 25, 2025, to ensure a regular and transparent process for shareholders [1][2][6] - The request is in response to shareholder concerns regarding the timely communication of resolutions aimed at changing the Board of Directors' composition [2][3] - The resolutions presented by a group of shareholders acting in concert have been renumbered from n°35 to 44 to A to K, with the content remaining unchanged [4] Company Information - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation [8] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [8] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [8]